Development of the first guideline for the standardization of health technology assessment in traditional Chinese medicine

Abstract

Health technology assessment (HTA) in the field of traditional Chinese medicine (TCM) is in its infancy, and its development has been relatively slow. The shifting disease burden pattern has driven a growing demand for TCM-HTA to optimize resource allocation, particularly in managing chronic diseases. To promote the development of TCM-HTA, it is important to address current TCM-HTA development issues in a targeted manner and enhance the TCM-HTA system to improve the quality and efficiency of limited health resource utilization. We systematically analyzed HTA methodological guidelines to summarize the development experiences of HTA organizations globally. The imperative development of HTA in the field of TCM should: a. Clarify the types of health technologies used in clinical TCM practice and define the objects of assessment. b. Develop technical specifications for the implementation of HTA in TCM. c. Choose appropriate assessment perspectives and involve patients, guided by their real needs and clinical problems. d. Formulate HTA methods and processes that reflect the characteristics of TCM. e. Establish a multi-level assessment model for teamwork, with a clear division of responsibilities and tasks among different members. This analysis will enable the development of guidelines for implementing HTA in TCM, based on current healthcare policies and the needs of clinical practice. These guidelines include the definition and classification of TCM health technologies, steps for implementing HTA in TCM, assessment domains, the TCM-HTA reporting checklist, and relevant explanations and data sources.

Keywords

health technology assessment / traditional Chinese medicine / guideline / standardization / development experience

References

[1] World Health Organization. Health Technology Assessment Survey 2020/21. https://www.who.int/data/stories/health-technology-assessment-a-visual-summary. Accessed November 1, 2024.

[2] O'Rourke B, Oortwijn W, Schuller T, International Joint Task Group. The new definition of health technology assessment: a milestone in international collaboration. Int J Technol Assess Health Care. 2020; 36(3):187-190.

[3] Joore M, Grimm S, Boonen A, de Wit M, Guillemin F, Fautrel B. Health technology assessment: a framework. RMD Open. 2020; 6(3):e001289.

[4] Health Technology Assessment international. What is HTA? https://htai.org/what-is-hta/. Accessed November 6, 2024.

[5] Chen Y, He Y, Chi X, Wei Y, Shi L. Development of health technology assessment in China: New challenges. Biosci Trends. 2018; 12(2):102-108.

[6] Wu X, Xu S, Dai Z, Liao X. Health technology assessment institutions and organizations: a scoping review. Chin J Exp Tradit Med Formulae. 2022; 28(20):178-185.

[7] Wu X, Jing C, Shi L, Liao X. Methodological guidelines for health technology assessment: a systematic review. Chin J Evid Based Med. 2024; 24(9):1021-1029.

[8] World Health Organization. Health Technology Assessment and Health Benefit Package Survey. https://www.who.int/teams/health-systems-governance-and-financing/economic-analysis/health-technology-assessment-and-benefit-package-design/survey-homepage. Accessed October 28, 2024.

[9] World Health Organization. HTA Country/Area Profile. https://cdn.who.int/media/docs/default-source/health-economics/hta-country-profiles-2020-21/hta_updated_merged_final.pdf?sfvrsn=75ac91f6_5. Accessed October 6, 2024.

[10] Chen Y, Zhao K, Liu G, et al. Health technology assessment to inform decision making in China: progress, challenges, and sustainability. BMJ. 2023; 381:e068910.

[11] Wang H, Jin C, Bai F, et al. Driving factors and mode transformation regarding health technology assessment (HTA) in China: problems and recommendations. Biosci Trends. 2019; 13(2):110-116.

[12] National Center for Medicine and Health Technology Assessment. Guideline for the management of clinical comprehensive evaluation of drugs (2020 edition). http://www.nhc.gov.cn/yaozs/s7656/202011/d11ddc32fae84121a0dfca36b015a31d/files/863665c55fd74f29a656990d1a4ea5ce.pdf. Accessed November 2, 2024.

[13] The Central Committee of the Communist Party of China and the State Council Issued the “Healthy China 2030” Planning Outline. https://www.gov.cn/zhengce/2016-10/25/content_5124174.htm. Accessed November 4, 2024.

[14] National Center for Medicine and Health Technology Assessment. Guideline for the management of clinical comprehensive evaluation of antineoplastic (2021 edition). http://www.nhei.cn/nhei/znfb/202206/c01d87a290664b01bf42a9dad769d69f/files/4e062c199b17474ca680da5aac3b6d89.pdf. Accessed November 1, 2024.

[15] National Center for Medicine and Health Technology Assessment. Guideline for the management of clinical comprehensive evaluation of pediatric drugs (2022 edition). http://cpia.org.cn/uploads/20220630/eef00a18bd641c9b3bbf213193df2730.pdf. Accessed November 1, 2024.

[16] National Center for Medicine and Health Technology Assessment. Guideline for the management of clinical comprehensive evaluation of cardiovascular drugs (2021 edition). http://nhei.cn/nhei/znfb/202112/9e350a54d2ea4c3ab9a0237ee4eab9f0/files/0ac56e4cd1e848da859d623212dd0171.pdf. Accessed November 1, 2024.

[17] Yuan WA, Zhang JH, Liu JP, et al. Guideline for clinical comprehensive evaluation of Chinese patent medicine (2022 version). China J Chin Mater Med. 2023; 48(1):256-264.

[18] Wu X, Wang WY, Liao X, Wang YY. Construction and content introduction of implementation standard of health technology assessment in traditional Chinese medicine. China J Chin Mater Med. 2024; 49(20):5643-5651.

[19] Chen YL, Yang KH, Wang XQ, et al. Guidelines for the development/revision of clinical diagnosis and treatment guidelines in China (2022 edition). Natl Med J China. 2022; 102(10):697-703.

[20] Moher D, Schulz K F, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010; 7(2):e1000217.

[21] Wu X, Li Z, Hu J, et al. Comprehensive evaluation of acupuncture for secondary dysmenorrhea based on health technology assessment. Chin J Exp Tradit Med Formulae. 2025; 31(9):165-174.

[22] Dai ZQ, Xu SM, Wu X, Li MM, Zhao H, Liao X. Feasibility analysis of EVlDEM framework in health technology assessment of traditional Chinese medicine. Chin J Exp Tradit Med Formulae. 2022; 28(6):175-181.

[23] Wu X, Zhang L, Jing C, Guo W, Liao X. Deliberative processes for health technology assessment: interpretation of the guideline from the Joint HTAi/lSPOR Task Force. Chin J Evid Based Med. 2024; 24(2):211-219.

[24] Oortwijn W, Husereau D, Abelson J, et al. Designing and implementing deliberative processes for health technology assessment: a good practices report of a Joint HTAi/ISPOR Task Force. Value Health. 2022; 25(6):869-886.

[25] Wu X. The Framework of Health Technology Assessment for TCM: Implementation Method and Case Study [dissertation]. Beijing, China: China Academy of Chinese Medical Sciences; 2024.

[26] World Health Organization. The world health report: health systems financing: the path to universal coverage. https://iris.who.int/bitstream/handle/10665/44371/9789241564021_eng.pdf. Accessed October 31, 2024.

[27] The Standing Committee of the 13th National People's Congress with the 7th meeting Report of The State Council on the allocation and use of financial medical and health funds. http://www.mof.gov.cn/zhengwuxinxi/caizhengxinwen/201812/t20181224_3102786.htm. Accessed December 2, 2024.

[28] International Decision Support Initiative. Health Technology Assessment Toolkit. https://www.idsihealth.org/htatoolkit/. Accessed November 1, 2024.

[29] Ning H, Wang Z, Chang H. Quantitative evaluation of provincial medical insurance policies specially supporting the development of TCM in China. World Chin Med. 2024; 19(8):1168-1175.